Arcadia Biosciences (RKDA) Form 3 Arcadia Biosciences / Thomas J. Schaefer ownership change

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0104
Estimated average burden
hours per response:	0.5

1. Name and Address of Reporting Person^*

Schaefer Thomas J.

(Last) (First) (Middle)

C/O ARCADIA BIOSCIENCES

202 COUSTEAU PLACE, SUITE 105

(Street)

DAVIS CA 95618

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
01/03/2023

3. Issuer Name and Ticker or Trading Symbol
Arcadia Biosciences, Inc. [ RKDA ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
Chief Financial Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	2,100	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(1)	07/27/2030	Common Stock	8,000	3.67	D
Stock Option (Right to Buy)	(2)	01/21/2031	Common Stock	4,000	3.05	D
Stock Option (Right to Buy)	(3)	10/01/2031	Common Stock	20,000	2.09	D
Stock Option (Right to Buy)	(4)	04/11/2032	Common Stock	23,000	1.27	D
Stock Option (Right to Buy)	(5)	04/11/2032	Common Stock	31,000	1.27	D
Stock Option (Right to Buy)	(6)	08/16/2032	Common Stock	23,000	0.94	D

Explanation of Responses:

1. The options were granted on 7/27/2020 and the vesting occurs as follows, subject to the Participant's continued service: (1) 25% of the shares vest on the first anniversary of the date of the award and (2) 75% of the shares vest in 36 equal installments, the first installment occurring on the last day of the month in which the initial vesting date occurs.

2. The options were granted on 1/21/2021 and the vesting occurs as follows, subject to the Participant's continued service: (1) 25% of the shares vest on the first anniversary of the date of the award and (2) 75% of the shares vest in 36 equal installments, the first installment occurring on the last day of the month in which the initial vesting date occurs.

3. The options will vest monthly in equal installments over a period of four years from the date of the grant, 10/1/2021, subject to the Participant's continued service.

4. The options will vest annually in equal installments over a period of two years from the date of the grant, 4/11/2022, subject to the Participant's continued service.

5. The options were granted on 4/11/2022 and the vesting occurs as follows, subject to the Participant's continued service: (1) 25% of the shares vest on the first anniversary of the date of the award and (2) 75% of the shares vest in 36 equal installments, the first installment occurring on the last day of the month in which the initial vesting date occurs.

6. The options will vest annually in equal installments over a period of three years from the date of the grant, 8/16/2022, subject to the Participant's continued service.

Remarks:

	Thomas Schaefer, by Attorney-in-fact, Solaeta Chan	01/05/2023
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.